TSN the sustainable nutrition group ltd

risk analysis, page-8

  1. 8,256 Posts.
    Taken from the latest release in relation to Chairman Santo,

    "the Company continues to develop HA-Irinotecan in metastatic colorectal cancer and the trial remains on track to reach its primary endpoint in the first half of 2014."

    Results anticipated Q1 2014 now look to be by end of Q2 (hopefully at the latest).

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.